WO2012115247A1 - Accélérateur de l'exfoliation de la couche cornée - Google Patents

Accélérateur de l'exfoliation de la couche cornée Download PDF

Info

Publication number
WO2012115247A1
WO2012115247A1 PCT/JP2012/054638 JP2012054638W WO2012115247A1 WO 2012115247 A1 WO2012115247 A1 WO 2012115247A1 JP 2012054638 W JP2012054638 W JP 2012054638W WO 2012115247 A1 WO2012115247 A1 WO 2012115247A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
stratum corneum
mesotrypsin
corneum peeling
ectoine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/054638
Other languages
English (en)
Japanese (ja)
Inventor
利彦 日比野
章子 山田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of WO2012115247A1 publication Critical patent/WO2012115247A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Definitions

  • the present invention provides a mesotrypsin expression promoter selected from the group consisting of ginkgo biloba extract, saxifrage extract, Izayoi rose extract, dipotassium glycyrrhizinate and ectoine, and a stratum corneum peeling promoter containing the same.
  • the outermost layer of the epidermis the stratum corneum (SC) consists of keratinized cells (keratinocytes) and a continuous extracellular lipid layer, forming a physiochemical barrier to effectively protect the body from environmental disasters.
  • SCs are created continuously through terminal differentiation of keratinocytes.
  • cell shedding occurs and the SC is maintained at a constant thickness.
  • individual keratinocytes or small aggregates detach from the skin surface. This process is undetectable in healthy people, but in some pathological conditions there is an imbalance between SC creation and ablation. The result is a visible excess scale. This is seen in inflammatory skin diseases such as psoriasis.
  • Non-patent Document 1 Lundstrom and Egelrud have reported that chymotrypsin-like serine protease exists in SC and is involved in detachment.
  • This enzyme was purified from human sole SC as a stratum corneum chymotrypsin enzyme, and a cDNA encoding the stratum corneum chymotrypsin enzyme was isolated from a human keratinocyte cDNA library (Non-patent document 2; Non-patent document). 3).
  • the present inventor has shown that not only chymotrypsin enzyme but also trypsin-like serine protease is involved in the SC exfoliation process other than the sole.
  • KLK7 stratum corneum chymotrypsin enzyme
  • KLK5 trypsin-like enzyme
  • KLK5 and KLK7 have a very important function in peeling.
  • trypsinogens are called cationic trypsinogen, anionic trypsinogen, and mesotrypsinogen based on their equipotential points. According to recent studies, these trypsinogens are encoded by different genes PRSS1, PRSS2, and PRSS3 (Non-patent Document 8). Trypsinogen 1 which is a PRSS1 gene product and trypsinogen 2 which is a PRSS2 gene product are major digestive pancreatic proteases. PRSS3 is a mesotrypsinogen gene and at least two splicing variants are generated (trypsinogen 3 and 4).
  • trypsinogens have the very highly conserved enteropeptidase-activated putative cleavage site sequence DDDDK-1 present in pancreatic trypsinogen from various species (Light and Janska, 1989) . Trypsinogen is expressed not only in the pancreas but also in other tissues, including epithelial cells of various tissues and the human brain. Interestingly, mesotrypsin differs from the other two trypsins in substrate specificity and inhibitor sensitivity. Mesotrypsin does not cleave protein substrates very much.
  • the inventor performed cDNA cloning of the trypsinogen gene from a human keratinocyte cDNA library, resulting in the isolation of two splicing isoforms of the mesotrypsinogen gene PRSS3, one of which is identical to trypsinogen 4 (brain trypsinogen), and The other was different only in the exon encoding the N-terminal region and was named trypsinogen 5 (Non-Patent Document 9).
  • Both isoforms have the activation sequence DDDDK-1.
  • DDDDK-1 is hardly cleaved by trypsin itself because of the presence of mainly negatively charged residues at the cleavage site.
  • enteropeptidase is highly specific for the DDDDK-1 sequence (Non-Patent Document 10).
  • the catalytic efficiency of enteropeptidase for bovine trypsinogen is 34,000 times that for bovine trypsin.
  • enteropeptidase is the only enzyme that physiologically converts trypsinogen to trypsin. It has also been found that enteropeptidase is present exclusively in the granular layer of the epidermis. The expression and location of these trypsinogens and their activating enzyme enteropeptidase is consistent with the view that mesotrypsin is involved in terminal differentiation of keratinocytes.
  • LEKTI serine protease inhibitor lympho-epithelial-casal-type 5 inhibitor
  • SPINK5-deficient mice show hyperproliferation of epidermal protease and show symptoms similar to Netherton syndrome through excessive degradation of desmoglen-1.
  • Multiple epidermal kallikreins may be involved in stratum corneum detachment through desmoglen 1 cleavage, and they are regulated by LEKTI.
  • stratum corneum detachment occurs when KLK acts on a desmosome that exhibits cell adhesion and decomposes it, and when LEKTI suppresses the action of KLK, stratum corneum detachment is also suppressed.
  • LEKTI suppresses the action of KLK
  • mesotrypsin was thought to promote stratum corneum peeling only by degrading LEKTI.
  • An object of the present invention is to provide a new stratum corneum peeling accelerator.
  • the stratum corneum peeling accelerator literally promotes the peeling of the stratum corneum, thereby exhibiting an effect of improving rough skin.
  • mesotrypsin not only degrades LEKTI, but surprisingly directly activates KLK7, which contributes to stratum corneum detachment. Therefore, as a result of screening candidate drugs that enhance the expression of mesotrypsin, it was found that Ginkgo biloba extract, Yukinosita extract, Izayoi rose extract, dipotassium glycyrrhizinate and ectoine have an effect of enhancing mesotrypsin expression, thereby completing the present invention.
  • a stratum corneum peeling promoter comprising the mesotrypsin expression enhancer of (1).
  • a method for promoting exfoliation of stratum corneum by applying to the skin a component selected from the group consisting of Ginkgo biloba extract, Yukinoshita extract, Izayoi rose extract, dipotassium glycyrrhizinate and ectoine to a subject who desires exfoliation promotion.
  • a component selected from the group consisting of ginkgo biloba extract, saxifrage extract, izayoi rose extract, dipotassium glycyrrhizinate and ectoine for promoting stratum corneum peeling.
  • ginkgo biloba extract, saxifrage extract, izayoi rose extract, dipotassium glycyrrhizinate and ectoine activate mesotrypsin, thereby exerting a stratum corneum peeling promoting effect, and as a result, rough skin is improved through peeling of the stratum corneum.
  • FIG. 5 shows that mesotrypsin has the ability to activate the precursor of KLK7 (proKLK7).
  • the mesotrypsin expression promotion effect of various crude drugs and drugs is shown.
  • the numerical value at the end of each herbal extract name represents the concentration ( ⁇ g / ml).
  • Corneal layer exfoliation promoter in one aspect, provides a stratum corneum exfoliation promoter comprising a mesotrypsin expression enhancer selected from the group consisting of ginkgo biloba extract, saxifrage extract, Isaiyo rose extract, dipotassium glycyrrhizinate and ectoine.
  • a mesotrypsin expression enhancer selected from the group consisting of ginkgo biloba extract, saxifrage extract, Isaiyo rose extract, dipotassium glycyrrhizinate and ectoine.
  • Izayoi rose extract has a ceramide synthesis promoting effect (Japanese Patent Laid-Open No. 2006-111560), a collagenase inhibitory effect (Japanese Patent Laid-Open No. 2006-241148), and the like.
  • dipotassium glycyrrhizinate and ectoin are also used for external preparations for skin, but none of the extracts is known to have a stratum corneum peeling promoting effect.
  • the above extract can be obtained by a conventional method.
  • a part or all of a plant that is the origin of the extract can be obtained by soaking or heating and refluxing together with an extraction solvent at room temperature or after heating, filtering and concentrating.
  • the extraction site may be dried.
  • the extraction solvent any solvent can be used as long as it is usually used for extraction.
  • organic solvents such as alcohols such as methanol, ethanol, propylene glycol, 1,3-butylene glycol and glycerin, hydrous alcohols , Chloroform, dichloroethane, carbon tetrachloride, acetone, ethyl acetate, hexane, or an aqueous solvent such as water, physiological saline, phosphate buffer, borate buffer, etc., either alone or in combination. it can.
  • one or more kinds selected from water, methanol, ethanol, and 1,3-butylene glycol are preferably used as the solvent.
  • the extract obtained by extraction with the above solvent can be used as it is or, for example, an extract concentrated by lyophilization or the like, and if necessary, an adsorbent method, for example, an ion exchange resin removed impurities, A polymer (eg, Amberlite XAD-2) adsorbed on a column, eluted with a desired solvent, and further concentrated can be used.
  • an adsorbent method for example, an ion exchange resin removed impurities,
  • a polymer eg, Amberlite XAD-2
  • Drugs such as Ginkgo biloba leaf extract, Yukinoshita extract, Isaiyoi rose extract, dipotassium glycyrrhizinate and ectoine show mesotrypsin expression enhancing action in a concentration-dependent manner. Therefore, from such a viewpoint, the amount of ginkgo biloba extract, saxifrage extract, Izayoi rose extract, dipotassium glycyrrhizinate and / or ectoine in the stratum corneum peeling promoter of the present invention is 0.
  • the content is 0001 to 20.0 mass%, preferably 0.0001 to 10.0 mass%.
  • the stratum corneum peeling accelerator according to the present invention can be produced according to a conventional method, and as the component constituting the stratum corneum peeling accelerator, it can be prepared by one or more of the above-mentioned extracts.
  • Ingredients used in skin preparations such as cosmetics and pharmaceuticals including quasi drugs, such as oils, surfactants, powders, coloring materials, water, alcohols, thickeners, chelating agents, silicones, antioxidants UV absorbers, moisturizers, fragrances, various medicinal ingredients, preservatives, pH adjusters, neutralizers, and the like are appropriately blended as necessary.
  • the dosage form of the stratum corneum peeling accelerator of the present invention is not particularly limited, and for example, a solution system, a solubilization system, an emulsification system, a powder dispersion system, a water-oil two-layer system, a water-oil-powder three-layer system.
  • Arbitrary dosage forms such as systems, ointments, gels, aerosols and the like can be taken.
  • the form of use is not particularly limited, and can take any form such as lotion, milky lotion, cream, essence, jelly, gel, ointment, pack, mask, foundation, and the like.
  • the stratum corneum peeling promoter of the present invention can be applied to the skin and used in a cosmetic method for preventing and / or improving rough skin.
  • the usage and dosage of the stratum corneum peeling promoter of the present invention in such a cosmetic method is not particularly limited, and is appropriately determined depending on the dosage form and the state of wrinkles on the skin to be treated.
  • Appropriate amount eg 0.1 to 1 ml per square cm 2 , can be rubbed directly into the skin, or the appropriate amount can be soaked in gauze or the like and applied to the skin.
  • RT-PCR Total RNA 500 ng isolated from human keratinocytes cultured as described above was reverse transcribed using random hexamers and Superscript II RNase H-reverse transcriptase (Gibco-BRL, Getersberg, MD) Thereafter, PCR amplification was performed using Taq DNA polymerase (Takara, Kyoto, Japan) and the following primers. 40 amplification cycles of 94 ° C. for 30 seconds, 60 ° C. for 1 minute, and 72 ° C. for 1 minute were performed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un amplificateur de l'expression de la mésotrypsine choisi dans le groupe constitué d'un extrait de Ginkgo biloba, d'un extrait de Saxifraga stolonifera, d'un extrait de Rosa roxburghii, de glycyrrhizate dipotassique et d'ectoïne, et un accélérateur de l'exfoliation de la couche cornée comprenant l'amplificateur de l'expression de la mésotrypsine.
PCT/JP2012/054638 2011-02-25 2012-02-24 Accélérateur de l'exfoliation de la couche cornée Ceased WO2012115247A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-039978 2011-02-25
JP2011039978 2011-02-25

Publications (1)

Publication Number Publication Date
WO2012115247A1 true WO2012115247A1 (fr) 2012-08-30

Family

ID=46721019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/054638 Ceased WO2012115247A1 (fr) 2011-02-25 2012-02-24 Accélérateur de l'exfoliation de la couche cornée

Country Status (2)

Country Link
TW (1) TW201309334A (fr)
WO (1) WO2012115247A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015143205A (ja) * 2013-12-27 2015-08-06 共栄化学工業株式会社 皮膚外用剤
JP2016003198A (ja) * 2014-06-16 2016-01-12 株式会社ファンケル カリクレイン７産生促進剤
WO2016063991A1 (fr) * 2014-10-24 2016-04-28 株式会社資生堂 Procédé de soin de beauté pour améliorer un état de la peau provoqué par une réduction ou une augmentation de la desquamation des cornéocytes, et procédé d'évaluation
JP2016108261A (ja) * 2014-12-04 2016-06-20 共栄化学工業株式会社 皮膚ターンオーバー改善剤
CN105919920A (zh) * 2016-06-23 2016-09-07 姹ゆ尝 一种抗皱抗衰美白祛斑面膜
WO2021018990A1 (fr) * 2019-08-01 2021-02-04 Merck Patent Gmbh Prévention et réduction des troubles de la kératinisation, et agents cosmétiques associés
JP2021091650A (ja) * 2019-05-23 2021-06-17 ポーラ化成工業株式会社 デスモグレイン減少剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000001421A (ja) * 1998-06-15 2000-01-07 Kanebo Ltd 皮膚老化防止化粧料
JP2002522367A (ja) * 1998-08-01 2002-07-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング エクトイン誘導体、酵素、ビタミンおよび／またはビタミン誘導体を含む化粧品製剤
JP2002302444A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 乾燥による皮膚傷害の抑制剤もしくは修復剤
JP2007119432A (ja) * 2005-10-31 2007-05-17 Ichimaru Pharcos Co Ltd ペルオキシソーム増殖剤応答性受容体活性化剤
JP2007277149A (ja) * 2006-04-06 2007-10-25 Kao Corp インボルクリン発現促進剤
JP2008088075A (ja) * 2006-09-29 2008-04-17 Kose Corp プロフィラグリン／フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮／角層正常化用皮膚外用剤、プロフィラグリン及び／又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000001421A (ja) * 1998-06-15 2000-01-07 Kanebo Ltd 皮膚老化防止化粧料
JP2002522367A (ja) * 1998-08-01 2002-07-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング エクトイン誘導体、酵素、ビタミンおよび／またはビタミン誘導体を含む化粧品製剤
JP2002302444A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 乾燥による皮膚傷害の抑制剤もしくは修復剤
JP2007119432A (ja) * 2005-10-31 2007-05-17 Ichimaru Pharcos Co Ltd ペルオキシソーム増殖剤応答性受容体活性化剤
JP2007277149A (ja) * 2006-04-06 2007-10-25 Kao Corp インボルクリン発現促進剤
JP2008088075A (ja) * 2006-09-29 2008-04-17 Kose Corp プロフィラグリン／フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮／角層正常化用皮膚外用剤、プロフィラグリン及び／又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOTARO NAKANISHI ET AL.: "Keratinocytes Synthesize Enteropeptidase and Multiple Forms of Trypsinogen during Terminal Differentiation", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 130, 19 November 2009 (2009-11-19), pages 944 - 952 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015143205A (ja) * 2013-12-27 2015-08-06 共栄化学工業株式会社 皮膚外用剤
JP2016003198A (ja) * 2014-06-16 2016-01-12 株式会社ファンケル カリクレイン７産生促進剤
WO2016063991A1 (fr) * 2014-10-24 2016-04-28 株式会社資生堂 Procédé de soin de beauté pour améliorer un état de la peau provoqué par une réduction ou une augmentation de la desquamation des cornéocytes, et procédé d'évaluation
JPWO2016063991A1 (ja) * 2014-10-24 2017-08-31 株式会社 資生堂 角層剥離の抑制又は亢進に起因する肌状態を改善するための美容方法及び評価方法
JP2016108261A (ja) * 2014-12-04 2016-06-20 共栄化学工業株式会社 皮膚ターンオーバー改善剤
CN105919920A (zh) * 2016-06-23 2016-09-07 姹ゆ尝 一种抗皱抗衰美白祛斑面膜
JP2021091650A (ja) * 2019-05-23 2021-06-17 ポーラ化成工業株式会社 デスモグレイン減少剤
WO2021018990A1 (fr) * 2019-08-01 2021-02-04 Merck Patent Gmbh Prévention et réduction des troubles de la kératinisation, et agents cosmétiques associés
CN114206300A (zh) * 2019-08-01 2022-03-18 默克专利股份有限公司 预防和减少角质化障碍及相关美容剂

Also Published As

Publication number Publication date
TW201309334A (zh) 2013-03-01

Similar Documents

Publication Publication Date Title
US11793864B2 (en) Use of serine protease inhibitors in the treatment of skin diseases
Lim et al. Flavonoids: broad spectrum agents on chronic inflammation
TW201309334A (zh) 角質層剝離促進劑
KR100844914B1 (ko) 탄력섬유형성의 불완전, 결여 혹은 해체로 인한 질병을제어하는 라이실 옥시다제의 동종효소의 활성 촉진
Kishibe et al. Kallikrein 8 is involved in skin desquamation in cooperation with other kallikreins
Hwang et al. Enzyme-modified Panax ginseng inhibits UVB-induced skin aging through the regulation of procollagen type I and MMP-1 expression
Di Paolo et al. The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets
CN107648341A (zh) 用于治疗和预防感染的植物提取物
AU2015296412A1 (en) Applications of surfactin in cosmetic products and thereof
Zani et al. Human tissue kallikreins-related peptidases are targets for the treatment of skin desquamation diseases
JP2021532064A (ja) デンドロビウム・ノビルを含有する組成物およびその使用方法
KR20230047688A (ko) 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도
Li et al. Shikonin inhibits inflammatory responses in rabbit chondrocytes and shows chondroprotection in osteoarthritic rabbit knee
Chen et al. Roles of kallikrein-related peptidase in epidermal barrier function and related skin diseases
KR101151093B1 (ko) 항염 및 피부 재생 효과를 갖는 화장료 조성물
JP4583501B2 (ja) マイタケ抽出物及びこれを含むヒアルロン酸（ヒアルロナン）産生を促進するための組成物
JP4585342B2 (ja) 不全角化を抑制する物質のスクリーニング方法、同方法によりスクリーニングされた物質及び不全角化を抑制する方法
JP6738280B2 (ja) 角層剥離の抑制又は亢進に起因する肌状態を改善するための美容方法及び評価方法
WO2019131406A1 (fr) Procédé de criblage d'agents améliorant l'état de la peau ayant une action inhibitrice de la thrombine en tant qu'indicateur, et agent améliorant l'état de la peau contenant un inhibiteur de l'action de la thrombine
KR102675065B1 (ko) 코나루스 세미데칸드러스 잎 추출물을 함유하는 아토피 피부염 개선용 화장료 조성물
JP6970952B2 (ja) カリクレイン関連ペプチターゼ産生促進剤、ｌｅｋｔｉ産生促進剤、ｓｌｐｉ産生促進剤、角化正常化剤、コルネオデスモソーム分解正常化剤
KR20150108088A (ko) 능실 추출물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물
WO2012124738A1 (fr) Agent de promotion de production de bléomycine hydrolase
JP2016135766A (ja) カリクレイン関連ペプチターゼ産生促進剤、ｌｅｋｔｉ産生促進剤、ｓｌｐｉ産生促進剤、角化正常化剤、コルネオデスモソーム分解正常化剤
CN119679655B (zh) 含棕榈酰三肽-5的组合物、护肤品和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12749399

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12749399

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP